Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Sollis Therapeutics

Request full access

Privately held pharmaceutical company developing non-opioid analgesic solutions

Columbus, United StatesFounded 2017Biotech & Life Sciences

About Sollis Therapeutics

Sollis Therapeutics is a healthcare startup that is focused on developing innovative treatments for sciatica pain. The company is currently working on an investigational therapy for patients who have not found relief from traditional sciatica pain treatments. Their primary product in development is the Clonidine Micropellet, a non-opioid, non-steroid medication designed to target the source of sciatica pain over time and reduce inflammation at the injured nerve.

The company operates in the healthcare and pharmaceutical market, specifically focusing on pain management. Their target clients are primarily patients suffering from sciatica pain, as well as clinicians seeking new interventions for treating this condition.

Sollis Therapeutics' business model revolves around the research, development, and eventual commercialization of their investigational therapy. The company is currently in the process of enrolling patients for their Phase 3 SERENITY CM study, which will provide further clinical evidence for the effectiveness of their treatment. Once the product has been thoroughly tested and approved, the company will generate revenue through the sale of the Clonidine Micropellet to healthcare providers and patients.

In summary, Sollis Therapeutics is a promising startup that is working to redefine the treatment of sciatica pain with a new, non-opioid, non-steroid medication. Their innovative approach could potentially provide a much-needed solution for patients who have not found relief from traditional treatments.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2017
Headquarters
Columbus, United States
Employees
27
Open positions
None listed
Dealroom signal
67.8/100
Industry
Health
Sub-industry
Pharmaceutical
Sector
Biotech & Life Sciences, Rehabilitation, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Apr 2018 $50M $200M Deerfield —
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Sollis Therapeutics website traffic

Latest recorded traffic for Sollis Therapeutics is 150 monthly website visits, down 21.1% over the last three months. Sollis Therapeutics's team declined 3.6% over the past year.

Latest monthly visits150 3-month web change-21.1% 1-year team growth-3.6%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Sollis Therapeutics in the Columbus ecosystem

Live from Dealroom

The Sollis Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Deerfield
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇺🇸 United States60%
🇳🇬 Nigeria20%
🇮🇳 India20%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Sollis Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Sollis Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.